Table 1 |
|||
|
|
|||
| NELFINAVIR |
LOPINAVIR/RITONAVIR |
p |
|
|
|
|||
| Age (yr) |
32 (28–36) |
32 (26–36) |
NS |
| C3 category |
21 (10) |
21 (19) |
0,026 |
| CD4 (cells/μL) at 1st visit |
477 (325–652) |
426 (264–600) |
NS |
| Viral load < 50 copies/ml at 3rd trimester |
142 (70) |
61 (62) |
NS |
| Hepatitis C |
79 (35) |
40 (33) |
NS |
| HAART-naive patients |
108 (48) |
35 (29) |
0.001 |
| Gestational diabetes mellitus |
15 (8) |
5 (5) |
NS |
| Vomiting |
9 (4) |
16 (14) |
<0.001 |
| Diarrhoea |
27 (12) |
15 (14) |
NS |
| Discontinuation of LPV or NFV. |
23 (10) |
12 (10) |
NS |
| Discontinuation of LPV or NFV due to virologic failure. |
1 (0.4) |
1 (0.8) |
NS |
| Vertical transmission |
1 (0.4) |
0 |
NS |
Peña et al. Journal of the International AIDS Society 2008 11(Suppl 1):P221 doi:10.1186/1758-2652-11-S1-P221 |
|||
